SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.
New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...
Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...
The EMA's human medicines committee has recommended approval of Amgen's bispecific T-cell engager (BiTE) – Imdylltra – as a second-line treatment option for extensive-stage small cell lung cancer ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody ...
Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results